ERBB2 and melanoma: Interestingly, a study comparing single-agent treatment using gefitinib, erlotinib or lapatinib versus the pan-ERBB inhibitor (targeting EGFR, ERBB2,3 and 4), canertinib (CI-1033), revealed increased ability of the multi-kinase inhibitor to reduce in vitro proliferation of both BRAF-wild-type (WT) and BRAFV600E melanoma cell lines (Ng et al., 2014).